资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 1月29日的资金流向数据方面，主力资金净流出1249.57万元，占总成交额6.11%，游资资金净流入 551.61万元，占总成交额2.7%，散户资金净流入697.96万元，占总成交额3.41%。 心脉医疗2025年三季报显示，前三季度公司主营收入10.15亿元，同比上升4.66%；归母净利润4.29亿 元，同比下降22.46%；扣非净利润3.72亿元，同比下降25.8%；其中2025年第三季度，公司单季度主营 收入3.0亿元，同比上升64.68%；单季度归母净利润1.14亿元，同比下降23.63%；单季度扣非净利润1.02 亿元，同比下降11.84%；负债率15.85%，投资收益1160.33万元，财务费用-785.84万元，毛利率 70.4 ...

证券之星消息，截至2026年1月28日收盘，心脉医疗(688016)报收于94.0元，下跌1.67%，换手率 1.29%，成交量1.59万手，成交额1.5亿元。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 1月28日的资金流向数据方面，主力资金净流出1034.32万元，占总成交额6.89%，游资资金净流入 1325.0万元，占总成交额8.82%，散户资金净流出290.68万元，占总成交额1.94%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 近5日资金流向一览见下表： 心脉医疗2025年三季报显示，前三季度公司主营收入10.15亿元，同比上升4 ...

Core Viewpoint - The stock of Xinmai Medical (688016) has shown a decline in price and mixed capital flow, indicating potential volatility in investor sentiment and market performance [1][2]. Group 1: Stock Performance - As of January 19, 2026, Xinmai Medical closed at 96.73 yuan, down 1.28% with a turnover rate of 1.17% and a trading volume of 14,500 hands, resulting in a transaction amount of 141 million yuan [1]. - Over the past five days, the stock has experienced a downward trend, with a total decline of 2.61% in main capital flow and a net outflow of 367.48 million yuan on January 19 [2]. Group 2: Financial Metrics and Industry Comparison - Xinmai Medical's total market capitalization is 11.923 billion yuan, slightly above the industry average of 11.393 billion yuan, ranking 30th out of 127 companies in the medical device sector [3]. - The company reported a net profit of 429 million yuan, significantly higher than the industry average of 208 million yuan, ranking 16th in the industry [3]. - The gross profit margin for Xinmai Medical stands at 70.4%, well above the industry average of 50.77%, indicating strong profitability [3]. Group 3: Recent Financial Performance - For the first three quarters of 2025, Xinmai Medical's main revenue reached 1.015 billion yuan, a year-on-year increase of 4.66%, while the net profit decreased by 22.46% to 429 million yuan [3]. - In Q3 2025, the company achieved a quarterly revenue of 300 million yuan, reflecting a substantial year-on-year increase of 64.68%, although the net profit for the quarter decreased by 23.63% [3]. Group 4: Analyst Ratings - In the last 90 days, eight institutions have provided ratings for Xinmai Medical, with seven recommending a buy and one suggesting an increase, indicating a generally positive outlook [4]. - The average target price set by institutions over the past 90 days is 136.03 yuan, suggesting potential upside from the current trading price [4].

Core Viewpoint - Xinmai Medical (688016) has shown mixed financial performance with a slight increase in revenue but a significant decline in net profit for the first three quarters of 2025 [2] Financial Performance - For the first three quarters of 2025, Xinmai Medical reported a total revenue of 1.015 billion yuan, representing a year-on-year increase of 4.66% [2] - The net profit attributable to shareholders decreased by 22.46% to 429 million yuan [2] - The net profit excluding non-recurring items fell by 25.8% to 372 million yuan [2] - In Q3 2025, the company achieved a quarterly revenue of 300 million yuan, marking a substantial year-on-year increase of 64.68% [2] - The quarterly net profit attributable to shareholders was 114 million yuan, down 23.63% year-on-year [2] - The quarterly net profit excluding non-recurring items was 102 million yuan, a decline of 11.84% [2] - The company's debt ratio stands at 15.85%, with investment income of 11.6 million yuan and financial expenses of -7.8584 million yuan [2] - The gross profit margin is reported at 70.4% [2] Market Activity - As of January 13, 2026, Xinmai Medical's stock closed at 98.82 yuan, with a slight increase of 0.39% [1] - The trading volume was 26,400 hands, with a total transaction value of 262 million yuan [1] - The net inflow of main funds was 7.5162 million yuan, accounting for 2.87% of the total transaction value [1] - Retail investors experienced a net outflow of 14.0856 million yuan, representing 5.38% of the total transaction value [1] Analyst Ratings - Over the past 90 days, eight institutions have provided ratings for Xinmai Medical, with seven giving a "buy" rating and one an "increase" rating [2] - The average target price set by institutions in the last 90 days is 1.3603 billion yuan [2]

Group 1 - The core viewpoint of the news is that Xinmai Medical (688016) has shown mixed financial performance, with revenue growth but a decline in net profit for the first three quarters of 2025 [2] - As of January 9, 2026, Xinmai Medical's stock closed at 97.94 yuan, up 1.25%, with a turnover rate of 1.42% and a trading volume of 17,500 hands, resulting in a transaction amount of 171 million yuan [1] - In terms of capital flow on January 9, 2026, the main funds had a net outflow of 838,300 yuan, accounting for 0.49% of the total transaction amount, while retail investors had a net inflow of 2.57 million yuan, accounting for 1.51% of the total transaction amount [1] Group 2 - Xinmai Medical's financial results for the first three quarters of 2025 show a main revenue of 1.015 billion yuan, a year-on-year increase of 4.66%, and a net profit attributable to shareholders of 429 million yuan, a year-on-year decrease of 22.46% [2] - The company's gross profit margin stands at 70.4%, with a debt ratio of 15.85% and investment income of 11.6 million yuan [2] - In the last 90 days, 8 institutions have rated the stock, with 7 buy ratings and 1 hold rating, and the average target price set by institutions is 136.03 yuan [2]

Core Viewpoint - The stock of Xinmai Medical (688016) has shown a positive performance with a closing price of 95.84 yuan, reflecting a 4.56% increase as of January 5, 2026, indicating strong market interest and potential growth in the medical device sector [1]. Financial Performance - Xinmai Medical reported a total revenue of 1.015 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 4.66% [4]. - The net profit attributable to shareholders for the same period was 429 million yuan, showing a decline of 22.46% year-on-year [4]. - The company achieved a gross margin of 70.4%, significantly higher than the industry average of 51.02% [4]. Market Position - Xinmai Medical's total market capitalization stands at 11.813 billion yuan, which is above the industry average of 11.28 billion yuan [4]. - The company ranks 16th in net profit within the medical device industry, with a net profit of 429 million yuan, compared to the industry average of 210 million yuan [4]. - The price-to-earnings (P/E) ratio for Xinmai Medical is 20.65, which is considerably lower than the industry average of 81.51, indicating a potentially undervalued stock [4]. Investment Sentiment - Over the past 90 days, 7 institutions have rated Xinmai Medical, with 6 giving a "buy" rating and 1 an "accumulate" rating, suggesting strong institutional confidence in the stock [5]. - The average target price set by institutions for Xinmai Medical is 136.03 yuan, indicating a potential upside from the current trading price [5]. Trading Activity - On January 5, 2026, the net inflow of main funds was 8.6933 million yuan, accounting for 3.74% of the total trading volume, while retail investors showed a net inflow of only 42,500 yuan [1]. - The financing data indicates a net purchase of 2.943 million yuan on the same day, reflecting positive investor sentiment towards the stock [2].

Group 1 - The core viewpoint of the article highlights the financial performance and stock movement of Xinmai Medical (688016) as of December 30, 2025, with a closing price of 91.6 yuan, reflecting a decline of 1.01% [1] - The company reported a main revenue of 1.015 billion yuan for the first three quarters of 2025, showing a year-on-year increase of 4.66%, while the net profit attributable to shareholders decreased by 22.46% to 429 million yuan [2] - In Q3 2025, the company achieved a single-quarter main revenue of 300 million yuan, a significant year-on-year increase of 64.68%, but the net profit attributable to shareholders fell by 23.63% to 114 million yuan [2] Group 2 - The company has a debt ratio of 15.85% and reported investment income of 11.6 million yuan, with financial expenses recorded at -7.8584 million yuan, indicating a strong financial position [2] - The gross profit margin for Xinmai Medical stands at 70.4%, reflecting the company's efficiency in managing production costs [2] - Over the past 90 days, 7 institutions have provided ratings for the stock, with 6 buy ratings and 1 hold rating, and the average target price set by institutions is 136.03 yuan [2]

Core Viewpoint - The stock of Xinmai Medical (688016) has shown a slight increase of 1.44% on December 25, 2025, closing at 93.88 yuan, with mixed capital flows indicating a net outflow from major and retail investors, while the stock remains well-positioned in the medical device industry based on key financial metrics [1][3]. Financial Performance - For the first three quarters of 2025, Xinmai Medical reported a main business revenue of 1.015 billion yuan, a year-on-year increase of 4.66%, while the net profit attributable to shareholders was 429 million yuan, a decrease of 22.46% [3]. - The third quarter of 2025 saw a single-quarter main business revenue of 300 million yuan, a year-on-year increase of 64.68%, but the net profit attributable to shareholders decreased by 23.63% to 114 million yuan [3]. Capital Flow Analysis - On December 25, 2025, the net outflow of major funds was 1.2198 million yuan, accounting for 1.32% of the total transaction amount, while retail investors saw a net inflow of 4.1196 million yuan, representing 4.46% of the total transaction amount [1][2]. - Over the past five days, the stock has experienced fluctuations in capital flow, with significant net outflows from major and speculative funds on certain days, indicating varying investor sentiment [2]. Industry Positioning - Xinmai Medical's total market capitalization stands at 11.572 billion yuan, with a net asset value of 3.982 billion yuan, and a net profit of 429 million yuan, positioning it favorably compared to the industry averages [3]. - The company has a gross margin of 70.4% and a net margin of 41.69%, ranking it second in the industry for net margin, indicating strong profitability relative to peers [3]. Analyst Ratings - In the last 90 days, eight institutions have provided ratings for Xinmai Medical, with six buy ratings and two hold ratings, and the average target price set at 136.03 yuan [4].

Core Viewpoint - The stock of Xinmai Medical (688016) has shown fluctuations in trading performance, with a recent closing price of 92.55 yuan, reflecting a 1.18% increase on December 24, 2025, amidst varying capital flows from different investor categories [1][2]. Group 1: Stock Performance and Capital Flow - On December 24, 2025, Xinmai Medical's stock closed at 92.55 yuan, with a trading volume of 7550 lots and a total transaction value of 69.46 million yuan [1]. - The net inflow of main funds was 1.87 million yuan, accounting for 2.69% of the total transaction value, while retail investors experienced a net outflow of 0.46 million yuan, representing 0.67% of the total [1]. - Over the past five days, the stock has seen significant fluctuations, with a peak net inflow of 2.99% on December 19, 2025, and a notable net outflow of 18.12% on December 23, 2025 [2]. Group 2: Financial Metrics and Industry Comparison - Xinmai Medical's total market capitalization is 11.408 billion yuan, slightly above the industry average of 10.878 billion yuan, ranking 28th out of 125 companies in the medical device sector [3]. - The company reported a net profit of 429 million yuan, significantly higher than the industry average of 210 million yuan, ranking 16th in the industry [3]. - The gross profit margin for Xinmai Medical stands at 70.4%, well above the industry average of 51.02%, indicating strong profitability [3]. Group 3: Recent Ratings and Analyst Outlook - In the last 90 days, eight institutions have rated Xinmai Medical, with six giving a "buy" rating and two an "accumulate" rating, suggesting a generally positive outlook [4]. - The average target price set by institutions over the past 90 days is 136.03 yuan, indicating potential upside from the current trading price [4].

Group 1 - The core viewpoint of the news is that Xinmai Medical (688016) has shown mixed financial performance in its recent quarterly report, with revenue growth but a decline in net profit [2] - As of December 22, 2025, Xinmai Medical's stock closed at 92.76 yuan, with a slight decrease of 0.04% and a trading volume of 7417 lots, amounting to a total transaction value of 68.92 million yuan [1] - In the recent funding flow data, there was a net outflow of 0.96 thousand yuan from main funds, while retail investors experienced a net outflow of 325.15 thousand yuan, indicating a shift in investor sentiment [1] Group 2 - For the first three quarters of 2025, Xinmai Medical reported a main revenue of 1.015 billion yuan, reflecting a year-on-year increase of 4.66%, while the net profit attributable to shareholders decreased by 22.46% to 429 million yuan [2] - The third quarter of 2025 saw a significant increase in revenue, reaching 300 million yuan, which is a 64.68% year-on-year growth, although the net profit for the quarter still declined by 23.63% to 114 million yuan [2] - The company has a debt ratio of 15.85% and a gross profit margin of 70.4%, indicating a strong financial position despite the profit decline [2]